Literature DB >> 27565564

Establishment of a simple cell-based ELISA for the direct detection of abnormal isoform of prion protein from prion-infected cells without cell lysis and proteinase K treatment.

Zhifu Shan1, Takeshi Yamasaki1, Akio Suzuki1, Rie Hasebe1, Motohiro Horiuchi1.   

Abstract

Prion-infected cells have been used for analyzing the effect of compounds on the formation of abnormal isoform of prion protein (PrP(Sc)). PrP(Sc) is usually detected using anti-prion protein (PrP) antibodies after the removal of the cellular isoform of prion protein (PrP(C)) by proteinase K (PK) treatment. However, it is expected that the PK-sensitive PrP(Sc) (PrP(Sc)-sen), which possesses higher infectivity and conversion activity than the PK-resistant PrP(Sc) (PrP(Sc)-res), is also digested through PK treatment. To overcome this problem, we established a novel cell-based ELISA in which PrP(Sc) can be directly detected from cells persistently infected with prions using anti-PrP monoclonal antibody (mAb) 132 that recognizes epitope consisting of mouse PrP amino acids 119-127. The novel cell-based ELISA could distinguish prion-infected cells from prion-uninfected cells without cell lysis and PK treatment. MAb 132 could detect both PrP(Sc)-sen and PrP(Sc)-res even if all PrP(Sc) molecules were not detected. The analytical dynamic range for PrP(Sc) detection was approximately 1 log. The coefficient of variation and signal-to-background ratio were 7%-11% and 2.5-3.3, respectively, demonstrating the reproducibility of this assay. The addition of a cytotoxicity assay immediately before PrP(Sc) detection did not affect the following PrP(Sc) detection. Thus, all the procedures including cell culture, cytotoxicity assay, and PrP(Sc) detection were completed in the same plate. The simplicity and non-requirement for cell lysis or PK treatment are advantages for the high throughput screening of anti-prion compounds.

Entities:  

Keywords:  PK-treatment; cell-based ELISA; monoclonal antibody; prion; screening

Mesh:

Substances:

Year:  2016        PMID: 27565564      PMCID: PMC5082968          DOI: 10.1080/19336896.2016.1189053

Source DB:  PubMed          Journal:  Prion        ISSN: 1933-6896            Impact factor:   3.931


  42 in total

1.  Anchorless prion protein results in infectious amyloid disease without clinical scrapie.

Authors:  Bruce Chesebro; Matthew Trifilo; Richard Race; Kimberly Meade-White; Chao Teng; Rachel LaCasse; Lynne Raymond; Cynthia Favara; Gerald Baron; Suzette Priola; Byron Caughey; Eliezer Masliah; Michael Oldstone
Journal:  Science       Date:  2005-06-03       Impact factor: 47.728

2.  Molecular characterization of chicken prion proteins by C-terminal-specific monoclonal antibodies.

Authors:  Naotaka Ishiguro; Yasuo Inoshima; Yukiko Sassa; Toyomi Takahashi
Journal:  Vet Immunol Immunopathol       Date:  2008-11-27       Impact factor: 2.046

3.  Characterization of intracellular dynamics of inoculated PrP-res and newly generated PrP(Sc) during early stage prion infection in Neuro2a cells.

Authors:  Takeshi Yamasaki; Gerald S Baron; Akio Suzuki; Rie Hasebe; Motohiro Horiuchi
Journal:  Virology       Date:  2014-01-15       Impact factor: 3.616

4.  Generating a prion with bacterially expressed recombinant prion protein.

Authors:  Fei Wang; Xinhe Wang; Chong-Gang Yuan; Jiyan Ma
Journal:  Science       Date:  2010-01-28       Impact factor: 47.728

5.  Mice devoid of PrP are resistant to scrapie.

Authors:  H Büeler; A Aguzzi; A Sailer; R A Greiner; P Autenried; M Aguet; C Weissmann
Journal:  Cell       Date:  1993-07-02       Impact factor: 41.582

6.  Synthesis and trafficking of prion proteins in cultured cells.

Authors:  A Taraboulos; A J Raeber; D R Borchelt; D Serban; S B Prusiner
Journal:  Mol Biol Cell       Date:  1992-08       Impact factor: 4.138

7.  Cell density-dependent increase in the level of protease-resistant prion protein in prion-infected Neuro2a mouse neuroblastoma cells.

Authors:  Satoshi Nakamitsu; Aya Kurokawa; Takeshi Yamasaki; Masahide Uryu; Rie Hasebe; Motohiro Horiuchi
Journal:  J Gen Virol       Date:  2009-10-07       Impact factor: 3.891

Review 8.  The prion's elusive reason for being.

Authors:  Adriano Aguzzi; Frank Baumann; Juliane Bremer
Journal:  Annu Rev Neurosci       Date:  2008       Impact factor: 12.449

9.  Anti-prion activity of a panel of aromatic chemical compounds: in vitro and in silico approaches.

Authors:  Natalia C Ferreira; Icaro A Marques; Wesley A Conceição; Bruno Macedo; Clarice S Machado; Alessandra Mascarello; Louise Domeneghini Chiaradia-Delatorre; Rosendo Augusto Yunes; Ricardo José Nunes; Andrew G Hughson; Lynne D Raymond; Pedro G Pascutti; Byron Caughey; Yraima Cordeiro
Journal:  PLoS One       Date:  2014-01-06       Impact factor: 3.240

10.  Detection and characterization of proteinase K-sensitive disease-related prion protein with thermolysin.

Authors:  Sabrina Cronier; Nathalie Gros; M Howard Tattum; Graham S Jackson; Anthony R Clarke; John Collinge; Jonathan D F Wadsworth
Journal:  Biochem J       Date:  2008-12-01       Impact factor: 3.857

View more
  2 in total

Review 1.  Neurotheranostics as personalized medicines.

Authors:  Bhavesh D Kevadiya; Brendan M Ottemann; Midhun Ben Thomas; Insiya Mukadam; Saumya Nigam; JoEllyn McMillan; Santhi Gorantla; Tatiana K Bronich; Benson Edagwa; Howard E Gendelman
Journal:  Adv Drug Deliv Rev       Date:  2018-10-26       Impact factor: 15.470

2.  Flow Cytometric Detection of PrPSc in Neurons and Glial Cells from Prion-Infected Mouse Brains.

Authors:  Takeshi Yamasaki; Akio Suzuki; Rie Hasebe; Motohiro Horiuchi
Journal:  J Virol       Date:  2017-12-14       Impact factor: 5.103

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.